跳至主要内容
临床试验/NCT04118530
NCT04118530已完成不适用

Long Term Arrhythmia Risk and Cardiovascular Events in Hematopoietic Stem Cell Transplant Survivors: Reveal Linq Cancer Registry Study

Abramson Cancer Center at Penn Medicine1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2021年4月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
21
试验地点
1
主要终点
Recurrent AF/AFL episodes

研究概览

简要总结

The purpose of this study is to better understand the following aims:

  1. Aim 1: To evaluate the rate of recurrent Atrial Fibrillation (AF)/Atrial Flutter (AFL) in hematopoietic stem call transplant (HCST) patients with incident AF/AFL identified during the initial 30 days of the transplant
  2. Aim 2: To evaluate incident episodes of 1) stroke/TIA; 2) other thromboembolic events (not stroke/TIA); 3) Heart failure events; 4) Ischemic heart events
  3. Aim 3: To evaluate overall implantation safety in this population

详细描述

We propose a registry study in hematopoietic stem cell transplant (HSCT) patients with incident atrial fibrillation/atrial flutter (AF/AFL) during the initial 30 days of transplant who will be implanted with the Medtronic Reveal Linq Implantable Cardiac Monitor (ICM) within 90 days of HSCT. We will evaluate the rate of recurrent AF/AFL as well as incident episodes of major cardiovascular events and the safety of ICM implantation in this population.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CHADS-VASc ≥ 2
  • Recovery of platelets to >50,000 within 90 days of incident atrial fibrillation (AF) diagnosis
  • Discharge from the incident stem cell transplant (SCT) hospitalization
  • Normal sinus rhythm at the time of consent

排除标准

  • Prior history of atrial fibrillation (AF) or atrial flutter
  • CHADS-VASc <2
  • Platelets <50,000 after 90 days post transplantation
  • Continued SCT hospitalization at 90 days
  • Inability to receive anticoagulation
  • AF or other arrhythmia at the time of consent
  • Current use of a class IC or III antiarrhythmic medication
  • Inability to provide informed consent/significant cognitive impairment
  • Expected survival less than one year.

结局指标

主要结局

Recurrent AF/AFL episodes

时间窗: 1 year

Any recurrent episodes of AF/AFL lasting ≥2 minutes identified in ICM monitoring

次要结局

  • Incident Episodes of Interest(1 year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验